Learning Center

Oil/Water emulsions are used in many pharmaceutical dosage forms to solubilize active ingredients, assist in skin penetration, and increase drug bioavailability. However, formulating emulsions is notoriously challenging due to a complex interplay between multiple competing forces, often leading to unstable formulations. As a result, current formulation approaches are empirical and paint an incomplete (and often inaccurate) picture of the emulsion landscape, complicating formulation development.

Hydrophile-Lipophile Difference / Net-Average Curvature (HLD-NAC) is a new, innovative approach for rational design of pharmaceutical emulsions. In an environment where fast, efficient product design is critical, HLD-NAC principles can significantly accelerate formulation development with minimal trial-and-error.

Watch our webinar with BASF Pharma Solutions expert Connor Bilchak and learn how BASF is enabling your emulsion formulation design with state-of-the-art science!

Webinar date: Apr 29, 2025

Lipid-based pharmaceutical excipients are frequently utilized in topical semisolid dosage forms due to their versatility and multifunctionality. Despite their long history of use, lipid-based pharmaceutical excipients continue to challenge beginner and expert formulators alike as these materials must be carefully balanced in often complex mixtures to achieve efficacious dermal drug delivery. To investigate the how to leverage lipid-based excipients to build stable and cosmetically elegant topical formulations, BASF has partnered with Mark Chandler of ACT Solutions Corp. We are pleased to have Mark take part in our webinar and present his work on using various stabilization techniques to address formulation challenges through the application of co-processed, self-emulsifying systems.

Webinar date: Jun 6, 2023

Coprocessed excipients provide solutions to simplify formulations and reduce manufacturing complexity, saving you time and money.

Kollitab™ DC 87 L is BASF’s new coprocessed excipient combining a filler, binder, disintegrant and lubricant, for direct compression tableting.

Learn what the formulation and parameter targets are to optimize direct compression formulations, and how to accelerate development with BASF’s new all-in-one fit-for-purpose tableting solution.

Webinar date: Nov 18, 2022

Continuous manufacturing is a future trend in solid dosage form manufacturing. Yet, it also faces challenges due to limitations in performance of different excipients used. The development and application of co-processed excipients has brought significant improvements to the flowability, compressibility and uniformity problems encountered in continuous manufacturing. Things are getting much easier.

BASF offers a wide range of co-processed excipients for a variety of formulations in direct compression, extended release, and orally disintegrating tablets. The new all-in-one excipient, Kollitab^TM DC 87 L, is the best choice for direct compression and continuous manufacturing processes. Watch the webinar video to learn more.

Please note: this webinar is conducted in Mandarin.

Webinar date: Jul 22, 2022

Softgels are a versatile single-unit dosage form. The successful development of PEG-based formulations requires an understanding of the manufacturing process, the potential shell/fill interactions and their impact on the product performance. The characteristics and the rational selection of shell and fill excipients are key topics of this event.

PEG is a unique excipient that offers a solution for formulating softgel hydrophilic fills and allows modulation of the fill viscosity that is in favor of good processability. However, careful evaluation is required based on the chemical attributes of the active ingredient to limit the formation of degradant products and ensure product stability during shelf life.

Webinar date: Nov 18, 2022

Dr. Nadya Morales-Cummings’ webinar will focus on sources of variability trends in the bioprocessing industry. Briefly, she will discuss the impact of raw material variability in bioprocesses and how variability in poloxamer 188 could impact bioprocesses performance. Nadya will present data on the impact of hydrophobic species present in poloxamer 188 on clonal and pooled cells and how BASF’s Kolliphor P188 Bio is an unlikely contributor to the trace metal variability trend in the industry.

Webinar date: Apr 14, 2021

Watch on demand now!

In disease states such as atopic dermatitis, excipient mildness plays an essential role in topical formulation development due to the skin’s predisposition to irritation and hypersensitivity. Driven by excipient selection, the optimization of patient outcomes and compliance can be achieved through the development of mild topical formulations.

This webinar will explore ingredient mildness and tolerability in relation to sensitive skin and atopic dermatitis. We are pleased to have Dr. Fowler take part in our webinar to discuss his experience in the identification of cutaneous allergy and irritancy through patch testing.

Webinar date: Apr 13, 2021

There is no one-size-fits-all solution to solubilization, but the industry is increasingly investigating practical solutions. BASF has designed 10 unique Self-Emulsifying Drug Delivery Systems (SEDDS), which can be easily reproduced to evaluate solubilization capability and bioavailability improvement for lead compounds at various product development stages.

Additionally, oral self-nanoemulsifying drug delivery systems (SNEDDS) have proven to increase the absorption of poorly soluble drugs. A frequent shortcoming is the relatively low drug dose that can be dissolved in the SNEDDS, thereby reducing their potential.

Webinar date: Jun 17, 2020